In the view that CTLs co-expressing TIM-3-PD-1 function more exhaustedly than those expressing PD-1 only, homogenously inhibiting TIM-3 and PD-1 may better prime T cells and strengthen their anti-tumor cytotoxicity (141, 142). The gene discussed is PDCD1; the disease is neoplasm.